{
  "meta": {
    "title": "Hiv_And_Nacp",
    "url": "https://brainandscalpel.vercel.app/hiv-and-nacp-c7ae1d9f.html",
    "scrapedAt": "2025-11-30T11:18:39.809Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">1 test is positive</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">2 tests are positive</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">3 tests are positive</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">4 tests are positive</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In ICTC, a patient is diagnosed to be HIV positive if the result of:</span></p>",
      "unique_key": "DT1231214",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231214,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>HIV diagnosis in ICTCs is confirmed only after three separate tests are positive, ensuring diagnostic accuracy and minimising false positives.</p>\r\n<ul>\r\n<li>Integrated Counselling and Testing Centres (ICTCs) are facilities under the National AIDS Control Programme (NACP) where individuals can voluntarily or provider-initiated undergo HIV testing after pre-test counselling.</li>\r\n<li>According to NACP guidelines, a patient is diagnosed as HIV-positive only if <strong>three independent tests</strong> (usually different ELISA or rapid tests based on different antigens or principles) are positive.</li>\r\n<li>This \"three-test\" protocol is implemented to ensure <strong>high specificity</strong> and reduce false positives that may arise from single or dual testing.</li>\r\n<li>The procedure involves:\r\n<ul>\r\n<li><strong>First test (Screening test):</strong> If positive, proceed to the second.</li>\r\n<li><strong>Second test (Confirmatory test):</strong> If also positive, then proceed to the third.</li>\r\n<li><strong>Third test (Final confirmation):</strong> If this is also positive, the individual is labelled HIV-positive.</li>\r\n</ul>\r\n</li>\r\n<li>If any discordance arises between the three tests, further evaluation or retesting after a window period is advised.</li>\r\n<li>This three-test approach is aligned with the <strong>WHO strategy</strong> and aims at <strong>maximum accuracy</strong> before initiating counselling, ART enrolment, and contact tracing.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925751abadf-c755-4d33-bf4b-9ce172a3683f.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>1 test is positive (Option A):</strong> Insufficient, as single-test positivity has the risk of false positives and is used only as a preliminary screen.</p>\r\n<p><strong>2 tests are positive (Option B):</strong> While it increases suspicion, it is still not adequate for a confirmed diagnosis under national guidelines.</p>\r\n<p><strong>4 tests are positive (Option D):</strong> Overly cautious and not part of NACP protocol, leading to unnecessary delays in treatment initiation.</p>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">4 weeks</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">6 weeks</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">12 weeks</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">18 weeks</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Early infant diagnosis (EID) of HIV infection can be made within:</span></p>",
      "unique_key": "DT1231222",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231222,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Early Infant Diagnosis (EID) of HIV is optimally done at <strong>6 weeks of age</strong> using HIV-DNA PCR to identify perinatal HIV transmission.</p>\r\n<ul>\r\n<li>The <strong>Prevention of Parent-to-Child Transmission (PPTCT)</strong> program under NACP aims to detect HIV infection in infants born to HIV-positive mothers at the <strong>earliest possible time</strong>.</li>\r\n<li>According to the national guidelines, <strong>EID should be done using HIV-DNA PCR at 6 weeks of age</strong>.</li>\r\n<li>This timing allows for detection of HIV infection <strong>before the onset of symptoms</strong>, enabling <strong>early initiation of ART</strong>, which significantly reduces morbidity and mortality.</li>\r\n<li>Testing before this age may yield false negatives due to <strong>low viral replication</strong>, and testing too late delays treatment initiation.</li>\r\n<li>If the 6-week PCR is negative and the child is still breastfeeding, follow-up tests are recommended at later intervals to monitor postnatal transmission.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025092545bc5b73-3da0-4aa7-b406-d910d65b4736.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>4 weeks (Option A):</strong> Though earlier testing is ideal in theory, 4-week testing is not the standard due to reduced sensitivity and higher false-negative rates.</p>\r\n<p><strong>12 weeks (Option C):</strong> Delays diagnosis and may postpone initiation of ART, risking progression of disease.</p>\r\n<p><strong>18 weeks (Option D):</strong> Considered too late for early intervention; increases infant morbidity and mortality.</p>",
      "correct_choice_id": 12,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Malaria</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">HIV</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Tuberculosis</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Kala-azar</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The Avahan program is a combined prevention approach for:</span></p>",
      "unique_key": "DT1231226",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231226,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The Avahan program is a targeted HIV prevention initiative focused on reducing transmission among high-risk populations in India.</p>\r\n<ul>\r\n<li>Launched by the <strong>Bill &amp; Melinda Gates Foundation</strong>, Avahan is one of the largest HIV prevention programs in the world.</li>\r\n<li>It follows a \"<strong>combination prevention\" strategy</strong>, which includes:\r\n<ul>\r\n<li>Condom promotion and distribution</li>\r\n<li>Behaviour change communication</li>\r\n<li>STI management</li>\r\n<li>HIV testing and counselling</li>\r\n<li>Community mobilization</li>\r\n<li>Linkage to care and ART services</li>\r\n</ul>\r\n</li>\r\n<li>The program primarily targets <strong>key populations at higher risk</strong> for HIV:\r\n<ul>\r\n<li>Female sex workers</li>\r\n<li>Men who have sex with men (MSM)</li>\r\n<li>Transgender individuals</li>\r\n<li>Injecting drug users (IDUs)</li>\r\n</ul>\r\n</li>\r\n<li>Avahan was implemented in partnership with Indian state governments and NGOs and later integrated into the National AIDS Control Programme (NACP).</li>\r\n<li>It contributed significantly to the <strong>decline in new HIV infections</strong> in high-burden states like Andhra Pradesh, Karnataka, Tamil Nadu, and Maharashtra.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509250b2f0e3c-6e5c-4bb2-86d8-6088b63df083.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Malaria (Option A):</strong> Managed under NVBDCP; not related to Avahan.</p>\r\n<p><strong>Tuberculosis (Option C):</strong> Managed under RNTCP/NTEP; Avahan is not a TB control program.</p>\r\n<p><strong>Kala-azar (Option D):</strong> A parasitic disease targeted under vector control programs; not part of Avahan's mandate.</p>\r\n<p><strong>Reference</strong>: <a href=\"https://www.unwomen.org/sites/default/files/Headquarters/Attachments/Sections/Library/Publications/2020/RESPECT-implementation-guide-Programme-summary-Avahan-en.pdf\" target=\"_blank\">RESPECT-implementation-guide-Programme-summary-Avahan-en.pdf (unwomen.org)</a></p>",
      "correct_choice_id": 22,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediately after exposure, followed by HIV testing at the end of the 3rd & 6th months</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediately after exposure, followed by HIV testing at the end of the 1st & 3rd months</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">HIV testing at the end of completion of prophylaxis, and also 2 months thereafter</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediately after exposure, followed by HIV testing at the end of completion of treatment</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Select the most appropriate recommendation for HIV testing after occupational post-exposure prophylaxis:</span></p>",
      "unique_key": "DT1231230",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231230,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Post-exposure prophylaxis (PEP) for HIV requires immediate testing and serial follow-up to monitor for seroconversion.</p>\r\n<ul>\r\n<li>HIV testing should begin <strong>immediately after occupational exposure</strong>, especially among healthcare professionals at risk due to <strong>needlestick injuries, mucosal contact, or non-intact skin exposure</strong>.</li>\r\n<li><strong>Standard follow-up testing</strong> includes retesting at the <strong>end of the 3rd and 6th months</strong> post-exposure.</li>\r\n<li>This extended testing schedule accounts for the <strong>window period</strong> in which HIV antibodies may not yet be detectable.</li>\r\n<li>According to PEP guidelines, this approach helps detect both <strong>early and delayed seroconversion</strong>, thereby ensuring accurate diagnosis and timely initiation of ART if required.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925c7014ff4-ce5d-4086-a735-0a9b1787da4c.png\"><br></li>\r\n<li>Recommended PEP regimens include 28 days of ART with drugs like <strong>raltegravir + emtricitabine + tenofovir</strong>, or <strong>dolutegravir + emtricitabine + tenofovir</strong>.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Immediately after exposure, followed by HIV testing at the end of the 1st &amp; 3rd months (Option B):</strong> Omits testing at 6 months, which is essential for detecting delayed seroconversion.</p>\r\n<p><strong>HIV testing at the end of completion of prophylaxis and also 2 months thereafter (Option C):</strong> Lacks immediate baseline testing and standard 3rd/6th month follow-ups; may miss early or delayed conversions.</p>\r\n<p><strong>Immediately after exposure, followed by HIV testing at the end of completion of treatment (Option D):</strong> Monitoring ends too early; doesn't align with WHO/PEP guidelines requiring 6-month testing.</p>",
      "correct_choice_id": 31,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Cytotoxic T-Lymphocytes Inducing vaccines</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Recombinant adeno-associated virus vaccine</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">AIDSVAX</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">All the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is considered as an AIDS vaccine?</span></p>",
      "unique_key": "DT1231235",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231235,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Multiple experimental platforms are under investigation as AIDS vaccine candidates, including CTL-inducing vaccines, viral vector-based approaches like rAAV, and protein subunit vaccines like AIDSVAX.</p>\r\n<ul>\r\n<li>An ideal AIDS vaccine should induce <strong>both cellular and humoral immune responses</strong> to prevent or control HIV infection.</li>\r\n<li>Various strategies are under study, and though <strong>none are fully protective yet</strong>, each of the listed types has shown potential in different stages of research and clinical trials:\r\n<ul>\r\n<li><strong>CTL-inducing vaccines</strong> aim to generate cytotoxic T lymphocytes that can eliminate HIV-infected cells.</li>\r\n<li><strong>Recombinant AAV vaccines</strong> deliver genes encoding HIV antigens and stimulate long-term immune responses.</li>\r\n<li><strong>AIDSVAX</strong>, a recombinant gp120 protein vaccine, was among the earliest HIV vaccine candidates tested in large-scale trials.</li>\r\n<li><strong>Modified Vaccinia Ankara (MVA)</strong> is also being used as a vector to deliver HIV genes and stimulate immunity.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025092550230d67-82b3-42d9-b7ab-d56a985c01f4.png\">\r\n<p><strong>(Other options ruled out)</strong></p>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Every 6 months</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Once every year</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Once every 2 years</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Whenever there is an HIV-related death</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">HIV Sentinel Surveillance is conducted:</span></p>",
      "unique_key": "DT1231239",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231239,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>HIV Sentinel Surveillance is carried out <strong>once every two years</strong> as a periodic, cross-sectional survey to monitor HIV prevalence among selected population groups.</p>\r\n<ul>\r\n<li>The objective is to detect trends in HIV prevalence among high-risk and general population groups such as:\r\n<ul>\r\n<li>ANC attendees (proxy for general population)</li>\r\n<li>Female sex workers (FSW), men who have sex with men (MSM)</li>\r\n<li>Injecting drug users (IDU), transgender persons (TG), and truckers</li>\r\n</ul>\r\n</li>\r\n<li>The surveillance is implemented using <strong>unlinked anonymous methods</strong> at sentinel sites, without identifying participants.</li>\r\n<li>This <strong>biennial frequency</strong> is optimal for detecting changes in HIV epidemiology over time without overburdening healthcare infrastructure.</li>\r\n<li>Surveillance results help in <strong>planning, monitoring, and prioritization of HIV control programs</strong> under the National AIDS Control Programme (NACP).</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925bbb4795b-d232-4d06-a46e-930fd2518479.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Every 6 months (Option A):</strong> Too frequent and resource-intensive; not necessary given slow-changing HIV trends.</p>\r\n<p><strong>Once every year (Option B):</strong> More frequent than required; may not offer significant added value compared to biennial surveys.</p>\r\n<p><strong>Whenever there is an HIV-related death (Option D):</strong> Not a surveillance strategy; reactive approach that fails to track epidemiological trends proactively.</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Type I pattern</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Type II pattern</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Type III pattern</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Type IV pattern</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">HIV epidemic in India follows which of the following patterns?</span></p>",
      "unique_key": "DT1231241",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231241,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>India's HIV epidemic is categorized as a <strong>Type IV pattern</strong>, marked by a complex interplay of multiple sub-epidemics involving both high-risk groups and the general population.</p>\r\n<ul>\r\n<li>The <strong>Type IV pattern</strong> includes simultaneous epidemics in:\r\n<ul>\r\n<li><strong>High-risk populations</strong> (e.g., MSM, FSWs, IDUs)</li>\r\n<li><strong>General population</strong> (especially via heterosexual transmission)</li>\r\n</ul>\r\n</li>\r\n<li>The transmission dynamics, prevalence, and affected groups vary widely across different <strong>states and regions in India</strong>.</li>\r\n<li>This pattern highlights a <strong>mixed epidemic</strong>, unlike classic single-route epidemics observed in earlier stages of the HIV pandemic globally.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509252585ac05-2769-437b-961f-fe816f830b3b.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Type I pattern (Option A):</strong> Seen in Western countries; driven mainly by homosexual transmission and not representative of India's diverse epidemic.</p>\r\n<p><strong>Type II pattern (Option B):</strong> Predominantly heterosexual transmission seen in sub-Saharan Africa; does not capture India's mixed epidemic nature.</p>\r\n<p><strong>Type III pattern (Option C):</strong> Describes initial concentration in high-risk groups followed by general spread; partially fits but doesn't reflect current stage in India.</p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ART now and continue till 6 weeks of delivery</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ART now and continue life long</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ART after first trimester and continue till 6 weeks of delivery</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Start ART after first trimester and continue life long</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A pregnant lady was found to be HIV positive in the first trimester. What is the appropriate line of management?</span></p>",
      "unique_key": "DT1231253",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231253,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The standard recommendation is to initiate <strong>lifelong ART</strong> immediately upon HIV diagnosis in pregnancy, regardless of trimester, to ensure viral suppression and prevent vertical transmission.</p>\r\n<ul>\r\n<li>ART should begin <strong>as soon as the diagnosis is made</strong>, even during the <strong>first trimester</strong>.</li>\r\n<li><strong>Triple-drug lifelong ART</strong> is the regimen of choice under the <strong>PPTCT</strong> strategy of NACP.</li>\r\n<li>Continuing ART beyond delivery is essential to prevent disease progression, reduce maternal morbidity, and minimize HIV transmission to the infant and sexual partners.</li>\r\n<li>Delaying ART or stopping it postpartum increases the risk of <strong>viral rebound</strong>, <strong>vertical transmission</strong>, and maternal disease progression.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509250a580671-f09d-404f-be15-cdf334c3a182.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Start ART now and continue till 6 weeks of delivery (Option A):</strong> Incorrect, as ART should be continued lifelong, not stopped postpartum.</p>\r\n<p><strong>Start ART after first trimester and continue till 6 weeks of delivery (Option C):</strong> Delaying ART increases transmission risk; stopping after delivery is outdated.</p>\r\n<p><strong>Start ART after first trimester and continue life long (Option D):</strong> Lifelong ART is correct, but delay in initiation is not recommended-treatment must begin immediately.</p>",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Antenatal women</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">STD clinic attendees</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Single male migrants</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Long distance truckers</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following are not included in sentinel surveillance of HIV in India?</span></p>",
      "unique_key": "DT1231256",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231256,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>HIV Sentinel Surveillance in India targets specific high-risk groups and proxy populations to monitor HIV trends. <strong>STD clinic attendees are not included</strong> in the official sentinel surveillance sites under NACP.</p>\r\n<ul>\r\n<li>The surveillance is conducted every 2 years using unlinked anonymous testing protocols.</li>\r\n<li>As per national guidelines, the designated groups under sentinel surveillance include:\r\n<ul>\r\n<li><strong>Antenatal clinic (ANC) attendees</strong> - proxy for general population</li>\r\n<li><strong>Female sex workers (FSW)</strong></li>\r\n<li><strong>Men who have sex with men (MSM)</strong></li>\r\n<li><strong>Injecting drug users (IDU)</strong></li>\r\n<li><strong>Transgenders (TG)</strong></li>\r\n<li><strong>Long-distance truckers</strong></li>\r\n<li><strong>Single male migrants</strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925ec09a5e6-6425-4a29-815f-643e878b99c3.png\">\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Antenatal women (Option A):</strong> Included in sentinel surveillance as a proxy for the general population; helps estimate HIV prevalence among women of reproductive age.</p>\r\n<p><strong>Single male migrants (Option C):</strong> High-risk group; included due to increased mobility and risk behaviours.</p>\r\n<p><strong>Long-distance truckers (Option D):</strong> Included because of occupational risk and mobility across regions; important for targeted interventions.</p>",
      "correct_choice_id": 82,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine + Lamivudine</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine + Lamivudine + Nevirapine</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenofovir + Lamivudine + Dolutegravir</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine + Stavudine + Nevirapine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">While taking a blood sample from an HIV-positive symptomatic patient, a resident doctor sustains a needle stick injury. What is the best regimen for post-exposure prophylaxis (PEP)?</span></p>",
      "unique_key": "DT1231262",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231262,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Tenofovir + Lamivudine + Dolutegravir</strong> is the preferred first-line post-exposure prophylaxis (PEP) regimen for healthcare workers following occupational exposure to HIV.</p>\r\n<ul>\r\n<li>PEP should be initiated <strong>as early as possible</strong>, preferably within 2 hours, and not beyond 72 hours of exposure.</li>\r\n<li>The regimen should be continued for <strong>28 days</strong>.</li>\r\n<li>The three-drug combination includes:\r\n<ul>\r\n<li><strong>Tenofovir (TDF)</strong> - a potent NRTI</li>\r\n<li><strong>Lamivudine (3TC)</strong> - another NRTI with synergistic efficacy</li>\r\n<li><strong>Dolutegravir (DTG)</strong> - an INSTI with high potency and barrier to resistance</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p>These drugs act on different stages of the HIV life cycle and are generally well-tolerated with minimal toxicity, making them ideal for PEP.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Zidovudine + Lamivudine (Option A):</strong> Two NRTIs, lacks a third drug, and <strong>Zidovudine has higher hematologic toxicity</strong>, making it less preferred for PEP.</p>\r\n<p><strong>Zidovudine + Lamivudine + Nevirapine (Option B):</strong> Nevirapine is hepatotoxic and <strong>not recommended for PEP</strong> due to long half-life and adverse effect risk.</p>\r\n<p><strong>Zidovudine + Stavudine + Nevirapine (Option D):</strong> Contains <strong>Stavudine</strong>, which is obsolete due to <strong>severe toxicities</strong> like peripheral neuropathy and lipoatrophy.</p>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">1st May</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">1st October</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">1st July</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">1st December</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">World AIDS Day is observed on -</span></p>",
      "unique_key": "DT1231264",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231264,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>1st December</strong> is observed globally as <strong>World AIDS Day</strong>. It is dedicated to raising awareness about the AIDS pandemic caused by the spread of HIV infection. The day serves to mourn those who have died from the disease and show solidarity and support for people living with HIV/AIDS.</p>\r\n<ul>\r\n<li>First observed in <strong>1988</strong>, World AIDS Day was the first-ever global health day.</li>\r\n<li>It is a key opportunity to educate the public, fight stigma, promote prevention strategies, and support universal access to treatment and care.</li>\r\n<li>It reflects ongoing efforts globally to reduce HIV incidence, ensure ART access, and combat discrimination.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>1st May (Option A):</strong> Celebrated as <strong>International Workers' Day</strong> or <strong>Labour Day</strong>, not related to HIV/AIDS awareness.</p>\r\n<p><strong>1st October (Option B):</strong> Recognised as <strong>International Day of Older Persons</strong>, focusing on elderly issues, not HIV/AIDS.</p>\r\n<p><strong>1st July (Option C):</strong> Observed as <strong>Doctors' Day</strong> in some countries, to honour medical professionals, not linked to HIV/AIDS awareness.</p>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Tears</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Urine</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Sweat</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Menstrual blood</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Exposure to which of the following fluids will require post-exposure prophylaxis (PEP) for HIV?</span></p>",
      "unique_key": "DT1231268",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231268,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Menstrual blood</strong> is considered a potentially infectious body fluid for HIV transmission. It may contain HIV-infected cells and virus particles, especially if it comes in contact with non-intact skin or mucous membranes. Therefore, significant exposure to menstrual blood warrants consideration for <strong>HIV post-exposure prophylaxis (PEP).</strong></p>\r\n<ul>\r\n<li><strong>PEP is indicated</strong> for exposure to fluids that have a high potential for transmitting HIV (e.g., blood, semen, vaginal secretions, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, synovial fluid, and amniotic fluid).</li>\r\n<li>Fluids like menstrual blood are explicitly categorised as <strong>potentially infectious</strong> due to their blood content.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Tears (Option A):</strong> Tears are not considered infectious unless visibly contaminated with blood; the risk of HIV transmission via tears is negligible.</p>\r\n<p><strong>Urine (Option B):</strong> Urine is not typically a carrier of HIV unless visibly bloody; therefore, exposure does not usually require PEP.</p>\r\n<p><strong>Sweat (Option C):</strong> Sweat is not a body fluid known to transmit HIV and does not require PEP after exposure.</p>",
      "correct_choice_id": 114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">HIV-infected infants and children do not progress rapidly to AIDS</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Seminal secretions are more infectious than vaginal secretions</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">HIV is infectious during the window period</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">HIV prevalence has not exceeded 5% in any subpopulation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Regarding the epidemiology of HIV, which of the following statements is not true?</span></p>",
      "unique_key": "DT1231273",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231273,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Option A is incorrect because HIV-infected infants and children, particularly those born with the infection, tend to progress rapidly to AIDS in the absence of treatment due to their immature immune systems.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925138e2b7a-6384-4c08-98bc-95cb8f64496b.png\">\r\n<p><strong>(Other options ruled out)</strong></p>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine + Lamivudine for 4 weeks</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Lamivudine + Tenofovir + Efavirenz for 4 weeks</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Lamivudine + Tenofovir + Dolutegravir for 4 weeks</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine + Lamivudine + Nevirapine for 4 weeks</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A resident doctor sustained a needlestick injury while sampling blood from a patient who is HIV positive. What is the best recommended post-exposure prophylaxis regimen?</span></p>",
      "unique_key": "DT1231276",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231276,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Lamivudine + Tenofovir + Dolutegravir for 4 weeks is the preferred PEP regimen due to its high efficacy, tolerability, and potency. This combination includes:</p>\r\n<ul>\r\n<li><strong>Tenofovir</strong> and <strong>Lamivudine</strong> - NRTIs that inhibit reverse transcriptase</li>\r\n<li><strong>Dolutegravir</strong> - an integrase strand transfer inhibitor (INSTI) with a favourable safety profile and potent activity</li>\r\n</ul>\r\n<p>This triple-drug combination provides effective coverage and minimizes the risk of viral resistance or adverse effects.</p>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925a5f63643-92fe-4747-a934-b4ebf28f31eb.png\">\r\n<p><strong>(Other options ruled out)</strong></p>",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Start 5 mg/kg/day isoniazid daily for 9 months</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Prophylaxis does not need to be started</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Rifabutin prophylaxis should be started</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Start 5 mg/kg/day isoniazid daily for 6 months</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old patient with HIV was screened for tuberculosis using the four-symptom screening tool and the result was negative. What is the next best step in management?</span></p>",
      "unique_key": "DT1231281",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231281,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Isoniazid preventive therapy (IPT) is recommended for HIV-positive individuals without evidence of active TB disease, even when screening tests are negative. This is because the immunocompromised state in HIV significantly increases the risk of progression from latent TB infection to active disease. A 6-month course of isoniazid (5 mg/kg/day) has been shown to reduce this risk effectively.</p>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Start 5 mg/kg/day isoniazid daily for 9 months (Option A):</strong> Although 9-month IPT is used in certain settings, the standard and widely accepted duration in asymptomatic HIV-positive patients is 6 months. Longer duration may increase pill burden and adverse effects without additional benefit in this case.</p>\r\n<p><strong>Prophylaxis does not need to be started (Option B):</strong> Despite the negative symptom screen, HIV-positive individuals remain at high risk for TB. WHO and NACO recommend IPT in such cases to reduce the incidence of TB.</p>\r\n<p><strong>Rifabutin prophylaxis should be started (Option C):</strong> Rifabutin is not used as a prophylactic agent for TB in HIV-positive individuals. It is mainly used as part of active TB treatment in select drug-resistant cases or in patients intolerant to rifampicin.</p>",
      "correct_choice_id": 144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">90% of all the patients living with HIV will know about their HIV status by 2020</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">90% of all people diagnosed with HIV will receive ART by 2020</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">90% of all people receiving ART will have a CD4 count in the normal range by 2020</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">90% of all people receiving ART will have viral load suppression by 2020</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is false regarding the 90-90-90 target for HIV/AIDS?</span></p>",
      "unique_key": "DT1231285",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231285,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The false statement is option <strong>C</strong> because the 90-90-90 strategy aims for <strong>viral load suppression</strong> in the third target, not normalisation of CD4 counts.</p>\r\n<ul>\r\n<li><strong>UNAIDS launched the 90-90-90 target in 2014</strong> to help end the AIDS epidemic by 2030.</li>\r\n<li>It consists of <strong>three sequential goals</strong> to be achieved by 2020:\r\n<ul>\r\n<li><strong>First 90:</strong> 90% of all people living with HIV should know their HIV status.</li>\r\n<li><strong>Second 90:</strong> 90% of all diagnosed HIV-positive individuals should be on antiretroviral therapy (ART).</li>\r\n<li><strong>Third 90:</strong> 90% of all individuals on ART should achieve <strong>viral load suppression</strong>.</li>\r\n</ul>\r\n</li>\r\n<li><strong>Viral load suppression</strong> means reducing HIV RNA in the blood to undetectable levels, which:\r\n<ul>\r\n<li>Improves health outcomes</li>\r\n<li>Prevents disease progression</li>\r\n<li>Reduces HIV transmission (\"U=U\" - Undetectable = Untransmittable)</li>\r\n</ul>\r\n</li>\r\n<li>CD4 count is an important marker of immune function, but <strong>normalisation of CD4</strong> is not the main outcome measure of the 90-90-90 target.</li>\r\n<li>The program emphasises <strong>population-level epidemic control</strong>, not just individual-level immune restoration.</li>\r\n<li>Achieving all three targets would mean:\r\n<ul>\r\n<li>90% tested &times; 90% treated &times; 90% suppressed = <strong>73% of all PLHIV virally suppressed</strong>.</li>\r\n</ul>\r\n</li>\r\n<li>The 90-90-90 target is a <strong>global public health goal</strong>, but progress varies across countries and regions.</li>\r\n<li>Key strategies to achieve targets:\r\n<ul>\r\n<li>Scaling up <strong>HIV testing services</strong> (community-based, facility-based, self-testing)</li>\r\n<li>Rapid initiation of ART after diagnosis (\"Test and Treat\" approach)</li>\r\n<li>Routine viral load monitoring to assess ART efficacy</li>\r\n<li>Addressing stigma, discrimination, and structural barriers to care</li>\r\n</ul>\r\n</li>\r\n<li>The <strong>next phase</strong>, after 2020, moves toward <strong>95-95-95 targets</strong> for 2030.</li>\r\n<li>The approach integrates with the <strong>Sustainable Development Goal (SDG) 3</strong> - \"Ensure healthy lives and promote well-being for all at all ages.\"</li>\r\n<li>Challenges in achieving targets:\r\n<ul>\r\n<li>Late diagnosis</li>\r\n<li>ART adherence issues</li>\r\n<li>Drug resistance</li>\r\n<li>Gaps in healthcare infrastructure in low-resource settings</li>\r\n</ul>\r\n</li>\r\n<li>Successful implementation requires <strong>multi-sectoral collaboration</strong>, political commitment, and continuous monitoring.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>90% of all the patients living with HIV will know about their HIV status by 2020 (Option A):</strong> True, this is the first target, aiming to increase HIV testing coverage.</p>\r\n<p><strong>90% of all people diagnosed with HIV will receive ART by 2020 (Option B):</strong> True, this is the second target, ensuring treatment access for those diagnosed.</p>\r\n<p><strong>90% of all people receiving ART will have viral load suppression by 2020 (Option D):</strong> True, this is the third target, aiming for control of HIV replication.</p>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Washing hands with soap and water</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Administration of tenofovir monotherapy</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Viral markers by the healthcare worker immediately for baseline</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Viral markers after six weeks</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A nurse sustained a needle stick injury while sampling the blood of a patient who is HIV positive. Which of the following is incorrect?</span></p>",
      "unique_key": "DT1231305",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231305,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Tenofovir monotherapy is not recommended for post-exposure prophylaxis (PEP) following a needlestick injury involving exposure to HIV-positive blood.</p>\r\n<ul>\r\n<li>Current guidelines recommend <strong>a combination of antiretroviral drugs</strong>, usually two NRTIs (e.g., tenofovir and emtricitabine) plus a third drug (protease inhibitor or integrase inhibitor) for 28 days.</li>\r\n<li>Combination therapy is essential to provide adequate coverage against HIV replication and to reduce the risk of resistance.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Washing hands with soap and water (Option A):</strong> Correct, this is an essential first-aid step after a needlestick injury to reduce the risk of infection by removing contaminants.</p>\r\n<p><strong>Viral markers by healthcare workers immediately for baseline (Option C):</strong> Correct, baseline HIV and other bloodborne pathogen testing should be done immediately to compare with follow-up results.</p>\r\n<p><strong>Viral markers after six weeks (Option D):</strong> Correct, follow-up testing at 6 weeks (and further at 3 and 6 months) helps detect early seroconversion and ensures prompt diagnosis if infection occurs.</p>",
      "correct_choice_id": 162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine and nevirapine - 6 months</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine and nevirapine - 6 weeks</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Nevirapine - 6 months</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Nevirapine - 6 weeks</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Mother is a known case of HIV, not on any treatment. Which of the following is the prophylaxis given for the newborn?</span></p>",
      "unique_key": "DT1231656",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231656,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>When a mother is a known case of HIV and is not on any treatment, prophylaxis to the newborn is essential to reduce the risk of vertical transmission during childbirth.</p>\r\n<ul>\r\n<li>The recommended regimen is <strong>zidovudine and nevirapine for 6 weeks</strong>.</li>\r\n<li>Zidovudine is usually started orally within 6-12 hours after birth and continued for 6 weeks.</li>\r\n<li>Nevirapine is typically administered as a single dose soon after birth.</li>\r\n<li>This combination significantly reduces the risk of HIV transmission in the early neonatal period.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Zidovudine and nevirapine - 6 months (Option A):</strong> Not recommended; extended prophylaxis beyond 6 weeks is not standard and may increase adverse effects without added benefit.</p>\r\n<p><strong>Nevirapine - 6 months (Option C):</strong> Monotherapy is not preferred; combination therapy offers better protection against transmission.</p>\r\n<p><strong>Nevirapine - 6 weeks (Option D):</strong> Not standard; nevirapine is used in combination with zidovudine for higher efficacy.</p>",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Candidiasis</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">PJP</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">MAC</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">CMV</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A HIV-positive patient with a CD4 count of <100 is at risk of developing which infection?</span></p>",
      "unique_key": "DT1231666",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231666,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The correct answer is MAC (Mycobacterium avium complex) because it is particularly associated with advanced HIV/AIDS and CD4 counts below 100 cells/mm<sup>3</sup>, often presenting as disseminated disease with high morbidity and mortality in untreated patients.</p>\r\n<p><strong>Opportunistic infections and CD4 count correlation:</strong></p>\r\n<ul>\r\n<li>Individuals with HIV/AIDS and progressively declining CD4 counts are prone to specific opportunistic infections at different thresholds.</li>\r\n<li><strong>MAC infection</strong> is strongly associated with CD4 counts <strong>&lt;100 cells/mm<sup>3</sup></strong>.</li>\r\n</ul>\r\n<p><strong>Key points about MAC:</strong></p>\r\n<ul>\r\n<li>Caused by Mycobacterium avium complex organisms.</li>\r\n<li>Commonly manifests as disseminated infection in advanced HIV.</li>\r\n<li>It can involve multiple organs (liver, spleen, bone marrow, intestines).</li>\r\n<li>Leads to severe morbidity and mortality if untreated.</li>\r\n<li>Prophylaxis against MAC is considered when the CD4 count drops below 50-100 cells/mm<sup>3</sup>.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Candidiasis (Option A):</strong> Common in HIV patients, especially with CD4 &lt;200 cells/mm<sup>3</sup>; not specifically linked to &lt;100 cells/mm<sup>3</sup>.</p>\r\n<p><strong>PJP (Option B):</strong> Strongly associated with CD4 &lt;200 cells/mm<sup>3</sup>; risk increases further with lower counts but not as specific as MAC for &lt;100 cells/mm<sup>3</sup>.</p>\r\n<p><strong>CMV (Option D):</strong> Seen in advanced HIV with severe immunosuppression, but not uniquely linked to CD4 &lt;100 cells/mm<sup>3</sup>.</p>",
      "correct_choice_id": 183,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">AFB stain</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">LPA</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">CBNAAT</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">LJ medium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The IOC for TB diagnosis in an HIV-positive patient is?</span></p>",
      "unique_key": "DT1231672",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231672,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The correct answer is <strong>CBNAAT</strong> because it is a <strong>highly sensitive and specific molecular test</strong> that can rapidly diagnose TB in HIV-positive patients and simultaneously detect <strong>rifampicin resistance</strong>, making it especially valuable in cases with <strong>smear-negative</strong> or <strong>paucibacillary specimens</strong>.</p>\r\n<ul>\r\n<li><strong>CBNAAT (Cartridge-Based Nucleic Acid Amplification Test)</strong>:\r\n<ul>\r\n<li>Detects <strong>Mycobacterium tuberculosis DNA</strong> and <strong>rifampicin resistance mutations</strong> in a single test.</li>\r\n<li><strong>Highly sensitive and specific</strong>, especially in <strong>smear-negative</strong> and <strong>paucibacillary</strong> cases, which are common in <strong>HIV-positive</strong></li>\r\n<li>Provides results in <strong>a few hours</strong>, enabling <strong>rapid treatment initiation</strong>.</li>\r\n<li>Helps in the <strong>early detection of drug-resistant TB</strong> for timely management.</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>AFB stain (Option A):</strong> Conventional microscopy for detecting acid-fast bacilli. Although rapid, it has <strong>lower sensitivity</strong> compared to molecular tests like CBNAAT. Sensitivity is further reduced in <strong>HIV-positive</strong> patients with <strong>low bacterial loads</strong>, leading to possible <strong>false negatives</strong>.</p>\r\n<p><strong>LPA (Option B):</strong> Molecular test to detect <strong>drug-resistance mutations</strong> in TB bacteria. While highly specific, it is <strong>not the first-line diagnostic</strong> in HIV-positive cases due to <strong>limited sensitivity</strong> in <strong>paucibacillary</strong> samples.</p>\r\n<p><strong>LJ medium (Option D):</strong> <strong>Gold standard</strong> solid culture method for TB. However, it is <strong>time-consuming</strong> (weeks for results). Delays in diagnosis can worsen outcomes and increase TB transmission; hence, rapid tests like CBNAAT are preferred in <strong>HIV-positive</strong> patients.</p>",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Rs 5 lakh per family per year is given</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Applied nutrition program</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Rs 10 lakh per family per year is given</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Formation of health and wellness centres</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not true about the Ayushman Bharat scheme?</span></p>",
      "unique_key": "DT1231673",
      "question_audio": null,
      "question_video": null,
      "map_id": 1231673,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The statement \"Rs 10 lakh per family per year is given\" is incorrect because the Ayushman Bharat scheme provides coverage of <strong>only up to Rs 5 lakh per family per year</strong>.</p>\r\n<ul>\r\n<li><strong>Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY)</strong> is a flagship health insurance scheme launched by the Government of India to provide <strong>financial protection</strong> to vulnerable families against <strong>catastrophic health expenditures</strong>.</li>\r\n<li><strong>Coverage:</strong> Up to <strong>Rs 5 lakh per family per year</strong> for secondary and tertiary care hospitalisation expenses.</li>\r\n<li>Implemented to reduce <strong>out-of-pocket expenditure</strong> and prevent impoverishment due to high medical costs.</li>\r\n<li>Launched along with the initiative to strengthen primary healthcare through <strong>Health and Wellness Centres (HWCs)</strong>.</li>\r\n<li>Integrated with <strong>preventive and promotive healthcare</strong></li>\r\n<li>Includes initiatives such as the <strong>Applied Nutrition Programme</strong> to address <strong>malnutrition</strong>, especially in women and children.</li>\r\n</ul>\r\n<p><strong>Explanation of Other Options:</strong></p>\r\n<p><strong>Rs 5 lakh per family per year is given (Option A):</strong> Correct; this is the official coverage limit under the scheme for eligible families.</p>\r\n<p><strong>Applied nutrition program (Option B):</strong> Correct; included in the scheme to improve nutritional outcomes and combat malnutrition.</p>\r\n<p><strong>Formation of health and wellness centres (Option D):</strong> Correct; the scheme aims to upgrade sub-health centres and PHCs into HWCs for comprehensive primary care.</p>",
      "correct_choice_id": 203,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}